https://s27.q4cdn.com/906368049/files/News/2022/Zacks_SCR_Research_09012022_CFRX_Bautz.pdf
HC Wainwright Raises Price Target On Outlook Therapeutics After Wet AMD Trial Data
H.C. Wainwright raised the price target on Outlook Therapeutics Inc (NASDAQ:OTLK) to $6 from $5 and reiterated a Buy rating. The Company…